Qatar’s Ministry of Public Health (MoPH) has issued a nationwide recall for all batches of Clasgen 0.05% eye drops. The decision follows internal investigations that revealed significant lapses in sterile manufacturing protocols and data integrity. These prescription drops, which are commonly used to manage chronic dry eye disease by curbing inflammation and boosting tear production, have been pulled from circulation to prevent any potential risks to patient health.

This move is part of a broader trend of rigorous health oversight across the Gulf region, where authorities are increasingly proactive in monitoring pharmaceutical and consumer products. Similar to recent recalls in the UAE—which have targeted contaminated face masks and mislabeled baby gripe water—the Qatari health officials are prioritizing consumer safety through swift regulatory intervention. Residents are encouraged to stay informed regarding these health advisories, as regional health ministries continue to enforce strict standards to ensure the safety and efficacy of medical supplies in the market.